Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18019500 | 0.81 | ATAD2 (0.52) | OPRM1OPRK1OPRL1ATAD2NOTUM | |
| SCHEMBL2675331 | 0.78 | ATAD2 (0.52) | OPRM1OPRK1OPRL1ATAD2NOTUM | |
| SCHEMBL31714491 | 0.76 | GRIN1 (0.42) | OPRM1OPRK1OPRL1 | |
| SCHEMBL3355838 | 0.76 | CHRM2 (0.47) | OPRM1OPRK1OPRL1 | |
| SCHEMBL5121645 | 0.75 | OPRM1 (0.45) | OPRM1OPRK1OPRL1ATAD2NOTUM | |
| SCHEMBL31714549 | 0.75 | OPRM1 (0.38) | OPRM1OPRK1OPRL1NOTUM | |
| SCHEMBL496099 | 0.75 | ATAD2 (0.51) | ATAD2BRD4 | |
| SCHEMBL12559542 | 0.74 | OPRM1 (0.56) | OPRM1OPRK1OPRL1 | |
| Hydrochloric Acid SCHEMBL3597662 | 0.73 | ATAD2 (0.50) | ATAD2BRD4 | |
| SCHEMBL7414811 | 0.72 | HTR2C (0.48) | OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333407-A1 | Compounds and Their Use for Treatment of Hemoglobinopathies | HBG1, HBG2, HBB | OPRM1 1778/4885OPRK1 2058/4885OPRL1 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.